Mineralys Therapeutics, Inc. (MLYS) Live Share Price, Invest From India

Mineralys Therapeutics, Inc. Stock Performance

as on October 6, 2026 at 6:59 am IST

Day's Low
Day's High
$22.97
Day's Price Range
$23.95
$23.28
1.33%
Downside
2.88%
Upside
52 Week's Low
52 Week's High
$22.30
52-Week Price Range
$47.65
$23.28
4.21%
Downside
104.68%
Upside

Mineralys Therapeutics, Inc. share price movements today

Previous Close: $23.63
Open: $23.77
Volume: 766.9K
Market Cap: $2.1B
Day's Low - High: $22.97 - $23.95
52 Week Low - High: $22.30 - $47.65

Mineralys Therapeutics, Inc. Historical Returns

1 Month Return: -16.24 %
3 Month Return: -14.66 %
1 Year Return: -37.91 %
3 Year Return: + 140.14 %
5 Year Return: 0 %

Mineralys Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Mineralys Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-4.24

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-5.57

Industry PE ratio

-11.70

PEG Ratio

0.05

EBITDA

-349.5M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-57.97%

Mineralys Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mineralys Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Mineralys Therapeutics, Inc.	StrongBuy	$2.1B	NA	-5.57	0.00%	0.00%
Revolution Medicines	StrongBuy	$44.3B	637.21%	-23.32	0.00%	0.00%
Moderna	Neutral	$75.9B	-42.79%	-23.81	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$127.9B	185.14%	29.14	86.04%	0.00%
Regeneron	Buy	$75.7B	33.45%	17.55	84.86%	0.50%

Stock Returns calculator for Mineralys Therapeutics, Inc. Stock including INR - Dollar returns

The Mineralys Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Mineralys Therapeutics, Inc. investment value today

Current value as on today

₹66,387

Returns

-₹33,613

(-33.61%)

Returns from Mineralys Therapeutics, Inc. Stock

-₹38,833 (-38.83%)

Dollar Impact

₹5,220 (+5.22%)

Analyst Recommendation on Mineralys Therapeutics, Inc. Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Mineralys Therapeutics, Inc.. Average target price of $48.5

Mineralys Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Mineralys Therapeutics, Inc..

What analysts predicted

52%UPSIDE

Target Price

$48.5

Current Price

$23.28

Analyzed by

5 Analysts

High

$56

Target

$48.50

Low

$49

Mineralys Therapeutics, Inc. target price $48.5, a slight upside of 52% compared to current price of $23.28. According to 5 analysts rating.

Indian Investors' Interest in Mineralys Therapeutics, Inc. Stock

Search interest for Mineralys Therapeutics, Inc. Stock has increased by 14% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 6, 2026 to October 6, 2026

Change:14% versus previous 30 day period

Mineralys Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	-	-	-	-	0	-	0	-
Operating Income	-35	-45	-60	-51	-44	-46	-41	-38	-45	-246
EBITDA	-31	-41	-56	-48	-42	-43	-36	-32	-39	-241
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-31	-41	-56	-48	-42	-43	-36	-32	-39	-241
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-31	-41	-56	-48	-42	-43	-36	-32	-39	-241
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Mineralys Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Income	-2	-18	-31	-84	-192	-170
EBITDA	-3	-19	-28	-71	-177	-154
Interest Expense	0	0	1	-	-	-
Depreciation	-	-	-	-	0	0
Income Before Tax	-3	-19	-29	-71	-177	-154
Income Tax Expense	-	-	-	-	-	-
Net Income	-3	-19	-29	-71	-177	-154
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Mineralys Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-31	-41	-56	-48	-42	-43	-36	-32	-39	-241
Operating Cash Flow	-19	-30	-50	-66	-45	-30	-28	-37	-39	-32
Investing Cash Flow	-55	7	79	83	-92	-42	-150	-103	-44	-185
Financing Cash Flow	116	0	0	0	189	9	295	96	24	243
Change in Cash	41	-22	29	16	50	-63	115	-44	-60	25

Mineralys Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-3	-19	-29	-71	-177	-154
Operating Cash Flow	-2	-14	-29	-81	-166	-142
Investing Cash Flow	-	-	-21	-160	114	-389
Financing Cash Flow	3	23	128	203	116	590
Change in Cash	1	9	77	-38	64	58

Global Institutional Holdings in Mineralys Therapeutics, Inc.

Check out the Institutions with significant holdings in Mineralys Therapeutics, Inc..

Funds	Holdings
Peter Kolchinsky	8.70%
James E. Flynn	4.48%
Vanguard	3.72%
iShares	3.53%
VANGUARD INDEX FUNDS	2.70%

See all

Insights on Mineralys Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 3 Years
In the last 3 years, MLYS has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 604.8%
NEGATIVE IMPACT
Price Dip
In the last 7 days, MLYS stock has moved down by -7.8%

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Organisation	Mineralys Therapeutics, Inc.
Headquarters	150 N. Radnor Chester Rd., Radnor, PA, 19087, US
Industry	Biotechnology
CEO	Jon Congleton

Key Management of Mineralys Therapeutics, Inc.

Name	Title
Dr. James J. Ferguson III, FACC, M.D.	Chief Medical Officer
Mr. Adam Scott Levy	CFO & Secretary
Mr. Jeffrey A. Munsie J.D.	Chief Legal Officer
Dr. Robert McKean Ph.D.	Senior Vice President of CMC
Ms. Jessica Ibbitson	Executive Vice President of Operations
Mr. Michael Tortorici Ph.D., Pharm.D.	Senior Vice President of Translational Medicine
Dr. Jon Congleton	President, CEO & Director
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.	Founder & Executive Director
Ms. Danielle Mahoney	Senior Vice President of Quality Assurance
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer

FAQs

What is Mineralys Therapeutics, Inc. share price today?

Mineralys Therapeutics, Inc. share price today is $23.28 as on October 6, 2026 at 1:29 am IST at the close of the market. Mineralys Therapeutics, Inc. share today touched a day high of $23.95 and a low of $22.97.

What is the 52 week high and 52 week low for Mineralys Therapeutics, Inc. share?

Mineralys Therapeutics, Inc. share touched a 52 week high of $47.65 on November 12, 2025 and a 52 week low of $22.30 on June 8, 2026. Mineralys Therapeutics, Inc. stock price today i.e. October 6, 2026 at 1:29 am IST is closed at $23.28,which is 51.14% down from its 52 week high and 4.39% up from its 52 week low.

What is Mineralys Therapeutics, Inc.'s market capitalisation today?

Mineralys Therapeutics, Inc. market capitalisation is $0.00T as on October 6, 2026 at 1:29 am IST.

How to invest in Mineralys Therapeutics, Inc. Stock (MLYS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mineralys Therapeutics, Inc. on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Mineralys Therapeutics, Inc. Stock (MLYS) from India?

Indian investors can start investing in Mineralys Therapeutics, Inc. (MLYS) shares with as little as ₹96.292503356934 or $1 (as of October 6, 2026 at 1:39 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹962.93 in Mineralys Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on October 6, 2026 at 1:39 am IST). Based on Mineralys Therapeutics, Inc. share’s latest price of $23.28 as on October 6, 2026 at 1:29 am IST, you will get 0.4296 shares of Mineralys Therapeutics, Inc.. Learn more about fractional shares .